This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Synerkine Pharma B.v.. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Sabine Versteeg: Innovator in Fusion Protein Technology
Introduction
Sabine Versteeg is a prominent inventor based in Tiel, Netherlands. She has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 2 patents to her name, her work focuses on innovative solutions for medical conditions.
Latest Patents
One of her latest patents involves a fusion protein comprising interleukin 13 and a regulatory cytokine. This invention includes a nucleic acid molecule encoding the fusion protein, a vector containing this nucleic acid, and a host cell that incorporates the nucleic acid or vector. The fusion protein or a gene therapy vector encoding it may be utilized in the prevention or treatment of conditions characterized by pathological pain, chronic pain, neuro-inflammation, and neurodegeneration.
Career Highlights
Sabine Versteeg is currently associated with Synerkine Pharma B.V., where she continues to advance her research and development efforts. Her innovative work has the potential to significantly impact therapeutic approaches in the medical field.
Collaborations
She collaborates with notable colleagues, including Niels Eijkelkamp and Cornelis Erik Hack, to further enhance her research initiatives.
Conclusion
Sabine Versteeg's contributions to fusion protein technology exemplify her commitment to advancing medical science. Her innovative patents and collaborative efforts position her as a key figure in the biotechnology sector.